Actively Recruiting
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
Led by Jules Bordet Institute · Updated on 2025-08-07
50
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery
CONDITIONS
Official Title
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age above 18 years
- Liver metastasis confirmed by standard imaging methods (MRI, FDG PET/CT)
- Treatment-naive or after neoadjuvant chemotherapy
- Scheduled for liver metastasis surgery
- ECOG Performance status of 2 or less
- Signed written informed consent
You will not qualify if you...
- Non-resectable liver metastases
- Pregnant or breastfeeding women
- Presence of another serious medical condition that may interfere with study completion, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Jules Bordet
Brussels, Belgium, 1070
Actively Recruiting
Research Team
L
Loubna Taraji, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here